Analysts think IRWD stock price could decrease by -54%
Dec 05, 2025, 12:25 PM
-10.05%
What does IRWD do
Ironwood Pharmaceuticals, based in Boston, develops GI products including LINZESS for IBS-C and CIC, and is advancing treatments like apraglutide for rare GI diseases and IW-3300 for visceral pain conditions. The company, which went public in 2010, employs 267 people.
5 analysts think IRWD stock price will decrease by -53.51%. The current median analyst target is $1.73 compared to a current stock price of $3.73. The lowest analysts target is $0.71 and the highest analyst target is $3.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.